Human Papillomavirus Infection Clinical Trials

Find Human Papillomavirus Infection Clinical Trials Near You

A Single-center, Randomized, Double-blind, Phase IV Lot-to-lot Consistency Clinical Trial in 18-30 Years-old Females in China to Evaluate Immunogenicity and Safety of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

To support international market access and comply with World Health Organization Prequalification requirements, this lot-to-lot consistency trial is planned for initiation. The goal of this clinical trial is to evaluate lot-to-lot immunogenicity and safety of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli) in 18-30 years-old females in China. The main question it aims to answer is: · Is immunogenicity consistent across three commercially produced batches of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia coli)? Researchers will compare the immune responses at 1 month post full vaccination to see if the lot-to-lot consistency of immunogenicity can be achieved. Participants will: * Visit the clinic site on Month 0, 1, 2, 6 and 7. * Take 3 doses of investigational vaccine on Month 0, 1 and 6. * Provide approximately 5.0 mL venous blood samples on Month 0 and Month 7. * Keep a diary of their adverse events (AEs) within 30 days after each vaccination. * Report serious adverse events (SAEs), adverse events of special interest (AESIs), and pregnancies occurring during the trial.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 30
Healthy Volunteers: t
View:

• Chinese female participants aged 18 to 30 years old who can provide legal identity documentation at screening, i.e., at least 18 years of age and less than 31 years of age;

• The trial participant is able to understand trial procedures and comply with protocol requirements (including biological sample collection, completion of diary/contact cards, and attendance of scheduled follow-up visits), and voluntarily signs the informed consent form;

• The trial participant agrees to avoid pregnancy and use effective contraceptive measures from the first vaccination through 1 month after completion of full vaccination;

• No prior history of sexually transmitted diseases (including syphilis, gonorrhea, chancroid, lymphogranuloma venereum, granuloma inguinale, etc.);

• No prior history of abnormal cervical screening results or cervical intraepithelial neoplasia (CIN).

Locations
Other Locations
China
Zhangping Center for Disease Control and Prevention
RECRUITING
Zhangping
Contact Information
Primary
Qiufen Zhang
qiufen_zhang@innovax.cn
+865926536555
Time Frame
Start Date: 2026-05-26
Estimated Completion Date: 2027-02-28
Participants
Target number of participants: 720
Treatments
Experimental: Cecolin 9 - Lot 1 group
Experimental: Cecolin 9 - Lot 2 group
Experimental: Cecolin 9 - Lot 3 group
Related Therapeutic Areas
Sponsors
Leads: Xiamen Innovax Biotech Co., Ltd

This content was sourced from clinicaltrials.gov

Similar Clinical Trials